Pacific Shuanglin Bio-pharmacy Co., Ltd. (SHE:000403)

Market Cap	12.27B -24.0%
Revenue (ttm)	2.38B -16.2%
Net Income	559.77M -32.4%
EPS	0.60 -31.9%
Shares Out	950.40M
PE Ratio	21.70
Forward PE	12.60
Dividend	0.38 (2.98%)
Ex-Dividend Date	n/a

Volume	6,568,595
Average Volume	7,833,026
Open	12.75
Previous Close	13.06
Day's Range	12.75 - 13.00
52-Week Range	12.62 - 19.13
Beta	0.54
RSI	43.88
Earnings Date	Apr 29, 2026

About SHE:000403

Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in research, development, production, and sales of blood products in China and internationally. The company offers human serum albumin, intravenous human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus and anti-tetanus human immunoglobulin, rabies patient immunoglobulin, human coagulation factor VIII, and human prothrombin complex; and freeze-dried intravenous human immunoglobulin (pH4), human fibrinogen, and intravenous hepat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 2,635
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000403

Financial Performance

In 2024, SHE:000403's revenue was 2.65 billion, an increase of 14.00% compared to the previous year's 2.33 billion. Earnings were 745.32 million, an increase of 21.76%.